Intervention

Tiotropium

ClinicalTrials.gov intervention label

Clinical trials93

Recruiting0

Common conditions12

Lead sponsors shown15

Clinical trials

60 shown

Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPDNCT07541378 · 2024-03-11

Effect of Tiotropium on Eye Findings in the Treatment of Chronic Obstructive Pulmonary DiseaseNCT06525051 · 2023-10-23

Phase 4 COPD and Suboptimal Inspiratory Flow RateNCT05165485 · 2022-01-07

Replication of the INSPIRE Trial in Healthcare Claims DataNCT05179512 · 2020-09-22

Replication of the POET-COPD Trial in Healthcare Claims DataNCT05083429 · 2020-09-22

Early Intervention Efficacy in COPDNCT04249310 · 2020-03-27

Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled AsthmaNCT03376932 · 2019-01-18

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT03474081 · 2018-03-29

Efficiency of Twice Daily Formoterol Versus Once Daily Tiotropium in Patients With GOLD A/B COPDNCT03258749 · 2017-11-01

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the DiskusNCT03240575 · 2017-08-14

Cardiovascular Function in COPD PatientsNCT03055988 · 2017-03-29

Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD PatientsNCT02969317 · 2017-02-24

Effect of Tiotropium + Olodaterol on Breathlessness in COPD PatientsNCT02853123 · 2016-09-22

Tiotropium/Formoterol Via Discair® vs Tiotropium Monotherapy or Tiotropium + Formoterol Free Combination TreatmentNCT02988869 · 2016-08-01

Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPDNCT02683109 · 2016-03-08

Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD)NCT02872090 · 2016-03-01

Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPDNCT02603393 · 2015-11-20

Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine ChallengeNCT02622243 · 2015-11-01

A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)NCT02518139 · 2015-09-01

Multiple Ascending Dose Study of TRN-157 in Stable Mild and Moderate AsthmaticsNCT02382510 · 2015-04-01

A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) SubjectsNCT02275481 · 2014-11-01

Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus TiotropiumNCT02257385 · 2014-10-15

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary DiseaseNCT02207829 · 2014-09-01

Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD PatientsNCT02125734 · 2014-04-01

Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPDNCT01959516 · 2014-02-01

Evaluation of Long-Acting Muscarinic Antagonists in COPDNCT02039050 · 2014-02-01

Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary DiseaseNCT01911364 · 2014-01-01

Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT01922271 · 2013-08-01

Efficacy in Walked Distance of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass (EMERALD)NCT02473237 · 2013-04-01

Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD PatientsNCT01727024 · 2013-04-01

A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD PatientsNCT02566031 · 2013-03-23

Indacaterol Versus Tiotropium on Dynamic Hyperinflation in COPDNCT01693003 · 2013-03-01

Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active ControlNCT01715311 · 2012-11-01

Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow LimitationNCT01610037 · 2012-10-01

A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) PatientsNCT01708057 · 2012-10-01

Efficacy and Safety of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass ExposureNCT05506865 · 2012-09-01

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®NCT01694771 · 2012-09-01

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®NCT01696058 · 2012-09-01

Beta Blocker Therapy in Moderate to Severe COPDNCT01656005 · 2012-08-01

Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT01613326 · 2012-06-01

The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT01574651 · 2012-05-01

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD PatientsNCT01533922 · 2012-03-01

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.NCT01533935 · 2012-02-01

Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)NCT01462929 · 2011-11-01

Tiotropium In Early Chronic Obstructive Pulmonary Disease Patients in ChinaNCT01455129 · 2011-11-01

The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)NCT01490125 · 2011-10-01

A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT01372410 · 2011-07-01

A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPDNCT01395888 · 2011-06-30

Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)NCT01290874 · 2011-03-30

Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT01285492 · 2011-01-01

Study of a Tiotropium Inhaler For Shortness of Breath in Advanced Non-Small Cell Lung CancerNCT01172925 · 2010-11-01

Safety and Efficacy Study of Glyco pMDI After Single and Repeated AdministrationNCT01176903 · 2010-08-01

Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese PatientsNCT01119937 · 2010-05-01

Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary DiseaseNCT01072396 · 2010-02-01

Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) PatientsNCT01068613 · 2010-01-01

Effect of Indacaterol on Inspiratory Capacity (IC)NCT01012765 · 2009-11-01

GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary DiseaseNCT00950807 · 2009-09-01

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)NCT00929110 · 2009-06-01

The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary DiseaseNCT00939211 · 2009-06-01

Exacerbation StudyNCT00845728 · 2009-03-01

Common conditions

Pulmonary Disease, Chronic Obstructive43 Chronic Obstructive Pulmonary Disease27 Chronic Obstructive Pulmonary Disease (COPD)12 COPD8 Asthma4 Bronchitis1 Chronic Bronchitis1 COPD (Chronic Obstructive Pulmonary Disease)1 Dyspnea1 Emphysema1 Glaucoma, Angle-Closure1 NSCLC1

Leading sponsors

Boehringer Ingelheim33 Novartis Pharmaceuticals17 GlaxoSmithKline9 AstraZeneca4 Brigham and Women's Hospital3 Novartis3 Chiesi Farmaceutici S.p.A.2 National Institute of Respiratory Diseases, Mexico2 Sumitomo Pharma America, Inc.2 University of Dundee2 Centre Hospitalier Universitaire de Besancon1 Giresun University1 Hamilton Health Sciences Corporation1 Huashan Hospital1 Irmandade Santa Casa de Misericórdia de Porto Alegre1

Trial status mix

COMPLETED84

TERMINATED4

UNKNOWN2

WITHDRAWN2

SUSPENDED1

Phase mix

PHASE336

PHASE429

PHASE214

PHASE15

NA2

EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.